We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
From May 2023 to May 2024
By Dean Seal
Shares of Decibel Therapeutics were markedly higher after the company signed a deal to be acquired by Regeneron Pharmaceuticals at a 43% premium from Tuesday's closing price.
The stock soared 77% to $4.95 in premarket trading. Shares were up by a third year-to-date when the market closed Tuesday.
The Boston-based company said Wednesday that it has agreed to be acquired by Regeneron for $4 a share.
The transaction includes an additional non-tradeable contingent value right to receive up to $3.50 a share in cash for hitting certain clinical development and regulatory milestones.
The deal is expected to close in the third quarter.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 09, 2023 09:19 ET (13:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
